Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Hikma Pharmaceuticals    HIK   GB00B0LCW083

News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

FTSE flirts with record level though sterling boost fades; Inmarsat jumps

share with twitter share with LinkedIn share with facebook
share via e-mail
06/01/2017 | 06:07pm CEST
A woman is seen through a car window as she walks past the London Stock Exchange

Britain's major share index climbed on Thursday, flirting with its record high level but underperforming European peers, while Inmarsat rose on merger speculation.

The FTSE 100 <.FTSE> was up 0.3 percent, with consumer staples and industrials stocks providing the top boosts to send it hovering near its highest intra-day level of 7,586.45 points hit on Wednesday.

A weaker sterling initially provided a boost to the London-listed multi-national firms, but the currency turned positive by the end of trading. Pressure on sterling has been intensifying over the past week as some opinion polls point to a tighter-than-expected race.

The latest poll published by the Times showed May's lead down to just 3 percentage points ahead of the opposition Labour party, with a week to go until the vote. [nL8N1IY3D3]

While the large-caps were ahead on the day, they underperformed the broader European index and were handily beaten by French and Italian equities.

UBS Wealth Management warned that the boost to the FTSE 100 from the weak pound could be turning stale.

"The UK equity market's tailwind from the weak pound is fading, and as we lap the currency low point during the second and third quarters of this year, the market will no longer receive a boost from currency effects," said deputy head of the UK investment office Caroline Simmons.

Mid-caps, which have been outpacing their larger counterparts, lagged slightly, up just 0.2 percent.

"We have seen a relative underperformance of domestic-focused UK equities as political risk increases alongside the perceived uncertainty of the Brexit outcome," said Edward Park, investment director at Brooks Macdonald.

But Inmarsat (>> Inmarsat Plc) gained 5.4 percent on the day, leading the way among European satellite companies, with France's SES (>> SES) and Eutelsat (>> Eutelsat Communications) also fuelled by speculation they could be takeover targets after sources said Softbank would let its planned $14 billion merger between OneWeb and Intelsat collapse.

Gains among large-caps were broad-based and broker calls helped some specific stocks stand out.

Private equity firm 3I Group (>> 3i Group plc) rose 3.2 percent after Barclays raised its price target on the stock, saying a trading update from Action management, which accounts for 30 percent of 3I's portfolio, was reassuring and the group was confident on cash generation.

Mediclinic (>> Mediclinic International PLC) however sank 3.4 percent, the top FTSE faller, after both Credit Suisse and Bank of America Merrill Lynch cut their rating on the private health-care provider.

Meanwhile mid-cap bus and rail company FirstGroup (>> FirstGroup plc) fell 5.7 percent after a 23-percent profit jump was overshadowed by its warning of a mixed trading outlook.

Challenger bank Aldermore (>> Aldermore Group PLC) fell 3 percent after Exane cut it to "underperform", citing slowing loan growth and an uptick in impairments.

Online car retailer Auto Trader (>> Auto Trader Group PLC) hit a record high after Barclays upgraded the stock to "overweight." Its shares were up 4.5 percent.

National Grid (>> National Grid plc), Taylor Wimpey (>> Taylor Wimpey plc) and Marks & Spencer (>> Marks and Spencer Group Plc) had all gone ex-dividend on the day.

Business support services firm G4S (>> G4S plc) and real estate investment trust Segro (>> SEGRO plc) were confirmed as the latest additions to the blue-chip index, with changes effective on June 16.

Intu Properties (>> Intu Properties PLC) and Hikma Pharmaceuticals (>> Hikma Pharmaceuticals Plc) were set to be demoted to the mid-cap index, as part of the quarterly review reshuffling stocks based on their relative size.

(Reporting by Helen Reid; Editing by Andrew Heavens)

By Helen Reid

share with twitter share with LinkedIn share with facebook
share via e-mail
06/01 FTSE flirts with record level though sterling boost fades; Inmarsat jumps
05/26 British shares up 0.34 pct Monday
05/23 HIKMA PHARMACEUTICALS : Participates in 2017 World Economic Forum in Jordan
05/19 European shares claw back gains after worst week in six months
05/19 FTSE climbs for fourth straight week, shrugging off Trump slump
05/19 Hikma trims full year revenue forecast on Advair U.S. launch delay
05/17 FTSE breaks nine-day winning streak as miners, British Land fall
05/17 HIKMA PHARMACEUTICALS : to Publish Report on its Alignment with UN Sustainable D..
05/15 British stocks close flat Thursday
05/12 Record close for FTSE as AstraZeneca soars
More news
Sector news : Pharmaceuticals - NEC
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/08 Jazz Keeps The Narcolepsy Market Awake
05/12 'MAJOR' REPRIEVE NUMBER TWO : Another Stumble For GlaxoSmithKline's Advair Block..
04/21 JAZZ PHARMACEUTICALS : Recent News Shows Just How Good It Really Is
03/30 GLAXOSMITHKLINE : Delay In Mylan's Advair Generic Is A Helpful Short-Term Boost,..
03/15 Hikma Pharmaceuticals' (HKMPF) CEO Said Darwazah on Full Year 2016 Results - ..
Financials ($)
Sales 2017 2 078 M
EBIT 2017 415 M
Net income 2017 223 M
Debt 2017 475 M
Yield 2017 1,53%
P/E ratio 2017 21,52
P/E ratio 2018 15,89
EV / Sales 2017 2,56x
EV / Sales 2018 2,30x
Capitalization 4 850 M
More Financials
Duration : Period :
Hikma Pharmaceuticals Technical Analysis Chart | HIK | GB00B0LCW083 | 4-Traders
Full-screen chart
Technical analysis trends HIKMA PHARMACEUTI...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 13
Average target price 25,4 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Said Samih Taleb Darwazah Chairman & Chief Executive Officer
Khalid Nabilsi Chief Financial Officer
Ibrahim Jalal Senior Vice President-Technical Affairs
Ragheb Al-Shakhshir Vice President-Research & Development
Mohammed Ali Khaldoun Al-Husry Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON18.42%367 520
NOVARTIS12.96%225 386
ROCHE HOLDING LTD.8.68%224 497
PFIZER5.20%203 487
MERCK AND COMPANY12.38%180 958
More Results